Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 123-130

  Singh, Mandeep ^a   Schwartz, Thomas L ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Antidepressants; Major depressive disorder; Vilazodone

Indexed keywords

AMIODARONE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUOXETINE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VILAZODONE;

ALCOHOLISM; ANIMAL BEHAVIOR; ANTIDEPRESSANT ACTIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EATING DISORDER; ELECTROCARDIOGRAPHY; EXPERIMENTAL MODEL; GASTROINTESTINAL DISEASE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; INTERNET; LABORATORY TEST; MAJOR DEPRESSION; MAZE TEST; MEDICAL DECISION MAKING; MEDLINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; THEORY; TREATMENT OUTCOME; VOCALIZATION; WEIGHT GAIN; XEROSTOMIA;

EID: 84930482645     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S20683     Document Type: Review

References (42)

1. Rush AJ, Triveda MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11): 1905-1917.
2. Schwartz TL, Stahl SM. Optimizing antidepressant management of depression: current status and future perspectives. In: Cryan JF, Leonard BE, editors. Depression: From Psychopathology to Pharmacotherapy. Basel, Switzerland: Karger; 2010;27:254-267.
3. Schwartz TL, Rashid A. Augmentation and combination pharmacotherapy trends in major depressive disorder: results of a brief survey of psychiatrists. J Clin Pharm Ther. 2007;32(1):28-31.
4. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
5. Papakostas GI. Use of atypical antipsychotics as augmentation for treatment-resistant major depressive disorder. Primary Psychiatry. 2008;15(11):44-47.
6. Nelson JC, Papakostas GI. Atypical antipyschotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Pyschiatry. 2009;166(9):980-991.
7. Stahl S. Essential Psychopharmacology: The Prescriber's Guide. Cambridge, UK: Cambridge University Press; 2011.
8. Pies R. Handbook of Essential Psychopharmacology. Washington, DC: American Psychiatric Press Inc; 1998.
9. Hudziak GW. Buspirone. Philadelphia, PA: Lipincott Williams & Wilkins; 2005.
10. Othmer E, Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry. 1987;48(5):201-203.
11. Duxon MS, Starr KR, Upton N. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635. Br J Pharmacol. 2000;130(7): 1713-1719.
12. Hogg S, Dalvi A. Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav. 2004:77(1):69-75.
13. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/ serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009;15(2):107-117.
14. Vilazodone FDA Package Insert. St Louis, MO: Forest Pharmaceuticals, Inc; 2011.
15. Sorbera LA, Rabassedi X, Silvestre J, Castaner J. Vilazodone hydrochloride: antidepressant-5-HT1A partial agonist-5-HT reuptake inhibitor. Drugs Fut. 2001;26(3):247-252.
16. Barowsky J, Schwartz TL. An evidence based approach to augmentation and combination strategies for treatment resistant depression. Psychiatry (Edgmont). 2006;3(7):42-61.
17. Trevedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
18. Athanasiou M, Reed C, Rickels K. Vilazodone, a novel, dualacting antidepressant: current status, future promise and potential for individualized treatment of depression. Per Med. 2009;6(2): 217-224.
19. Stahl SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr. 2010;15(2):79-94.
20. Stahl S. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry. 2009;70(11):1493-1494.
21. Maes M, Meltzer H. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Pyschopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 2000:933-944.
22. Coplan JD, Wolk S, Klein D. Anxiety and the serotonin 1a receptor. In: Bloom FE, Kupfer DJ, editors. Pyschopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 2000.
23. Pellow S, Chopin P, File E, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-167.
24. Treit D. A comparison of anxiolytic and nonanxiolytic agents in the shock-probe burying test for anxiolytics. Pharmacol Biochem Behav. 1990;36(1):203-205.
25. Treit D, Menard J, Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav. 1993;44(2):463-469.
26. Adamec R, Burton P. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004;504(1-2):65-77.
27. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997;8(6-7):523-532.
28. Page ME, Detke MJ, Dalvi A, et al. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Pyschopharmacology (Berl). 1999;147(2):162-167.
29. Kehne JH, Bartoszyk GD, Greiner HE, et al. In vitro characterization of vilazodone as a dual-acting serotonin reuptake receptor and 5-HT1A receptor partial agonist. Poster presented at: 65th Annual Meeting of the Society of Biological Psychiatry Meeting; May 2010; New Orleans, LA.
30. Murck H, Antonijevic LA, Steiger A. Distinct temporal pattern of the effects of combined serotonin-re-uptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology. 2001;155(2):187-192.
31. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs. 2011;25(7):615-627.
32. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, doubleblind, placebo-controlled trial. J Clinical Psychiatry. 2009;70(3): 326-333.
33. APA American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Publishing; 2000.
34. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1 year open-label study assessing the safety and tolerabilty of vilazodone in patients with major depressive disorder. J Clin Pyschopharamcol. 2011;31(5):643-646.
35. Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Pyschiatry. 2011;72(9):1166-1173.
36. Stahl S. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge, UK: Cambridge University Press; 2008.
37. Grant BF, Harford TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39(3):197-206.
38. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1990;147(6):798-800.
39. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessivecompulsive disorder. Am J Psychiatry. 1993;150(4):647-649.
40. Schneier FR, Jihad B, Raphael C, et al. Buspirone in social phobia. J Clin Psychopharmacol. 1993;13(4):251-256.
41. Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol. 2000;27(5):509-513.
42. American Psychiatric Association. American Psychiatric Association Practice guideline for major depressive disorder in adults. American Psychiatric Association. Am J Psychiatry. 2010;150:1-26.